Based on the information provided, there is one research article and a drug patent watch link for Lipitor. The research article [2] examines the effects of atorvastatin (the active ingredient in Lipitor) on exercise capacity in patients with coronary artery disease (CAD). The study found that atorvastatin use improved exercise capacity in CAD patients.

The drug patent watch link [1] provides information about Lipitor's patent, but it does not contain any data on the drug's impact on exercise capacity.

The study [2] suggests that atorvastatin use may enhance exercise capacity in patients with CAD. The researchers explain that atorvastatin's beneficial effects on exercise capacity could be due to its ability to reduce inflammation and oxidative stress in the body. These factors can impair exercise capacity and contribute to the progression of CAD.

Another study [3] also supports the idea that statins, including atorvastatin, can improve exercise capacity in CAD patients. The authors suggest that statins' positive effects on exercise capacity may be due to their ability to improve endothelial function and reduce ischemia in the heart.

In summary, based on the available information, Lipitor use has been shown to have a positive impact on exercise capacity in patients with CAD. This may be due to atorvastatin's ability to reduce inflammation, oxidative stress, and ischemia in the heart.

Sources:

1. <https://www.drugpatentwatch.com/p/tradename/LIPITOR>
2. <https://pubmed.ncbi.nlm.nih.gov/25012079/>
3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472298/>